Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,001–3,100 of 3,704
Obesity and female reproductive health in Asian population
Panyakhamlerd, K., Sophonsritsuk, A., Pantasri, T., Suwan, A., Panyawongudom, N., & Samakkarnthai, P. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100255 · Cited by 1
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
Midlife weight gain: challenges and solutions
Hung, S., & Adams, K. E. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001093 · Cited by 1
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Inkretinmimetika und Schilddrüsenkrebs: Gibt es ein Risiko?
Parzer, V. (2026) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-026-00297-7
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Krzystek, Ł., Buć, K., Buć, P., Mazurek, M., Józefczyk, J., Zieliński, K., Ganczar, K., Jurkowski, S., Rudzińska, M., & Zalewski, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4388
Dallal, R. M., Das, A., Pribitkin, E. A., Beekley, A. C., Tatarian, T., Malhotra, D. K., Harrison, T. D., & Yeo, C. J. (2026) · Annals of Surgery · doi:10.1097/sla.0000000000007039
Kanumilli, N., Osumili, B., Evans, J., Webb, J., Buckingham, M., Debackere, N., Nowakowski, P., Cattin, J., & Hunt, B. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2631920
Neue Medikamente zur Gewichtsreduktion – ethische Herausforderungen
Weidinger, I. S. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2748-4530
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Sobiński, A., Sadowska, A., Welkier, A., Miśkiewicz, J., Dudek, A., Pietrusińska, P., Moder, J., Dziewierz, A., Kwaśniewska, P., & Śliwa-Tytko, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4326
Saldívar-Cerón, H. I. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010021
The evolution of obesity pharmacotherapy from sympathomimetics to incretin-based therapies
Ncube, K. N., Moloi, N., & Malange, T. D. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4108 · Cited by 1
Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus
Henson, J. J., Davies, M. J., Greaves, C., Khunti, K., & Yates, T. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00003-3
Moize, V. L., Piaggi, P., Martínez-Saludes, I., Torres, F., Viaplana, J., Jiménez, A., de Hollanda, A., Ibarzábal, A., & Vidal, J. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08561-0
Khatib, O. E., Chiha, M., Jarad, O., Salloum, C., Baba, K. E., Dajani, R., Shaqfa, S. A., & Hajj, S. E. (2026) · Experimental and Clinical Transplantation · doi:10.6002/ect.2025.0180 · Cited by 1
Kim, M., Van, J. Y., Park, S., Hwang, J. Y., Seong, Y., Park, Y. J., Lee, S., Ryu, B., Jun, J. Y., Jung, W., et al. (2026) · Food Frontiers · doi:10.1002/fft2.70246 · Cited by 1
Heerspink, H. J. L., van Raalte, D. H., Tuttle, K., Cherney, D. Z. I., Bjornstad, P., Cao, D., Dimitriadis, G. K., Linetzky, B., Jouravskaya, I., Bunck, M. C. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70622 · Cited by 2
Self-citationABBA, V., Nielsen, A. B. E., Buhr, P., Hammelev, K. P., Holst, J. J., & Lobato, C. B. (2026) · Anesthesia Research · doi:10.3390/anesthres3010006
Moiz, A., Reynier, P., Tsoukas, M. A., Yu, O. H., Peters, T. M., Eisenberg, M. J., & Filion, K. B. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03153-6
Xu, H., Hu, W., Ln, Z., Tu, W., Shen, L., Zhang, G., ZHONG, L., Liu, J., XU, J., & Li, X. (2026) · Obesity · doi:10.1002/oby.70160
Effects of anti-obesity medications in the retina: a gathering storm or sunshine ahead?
Muir, A.-M., Lee, H., Lotery, A. J., & Ratnayaka, J. A. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-329298
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Nicze, M., Borówka, M., Dec, A., Bułdak, Ł., Bołdys, A., & Okopień, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062539 · Cited by 7
Real‐World Weight Loss Is Associated With a Reduction in Cancer Risk
Alkwatli, K., Xiao, H., Mariam, A., Lopetegui, N. M., Griebeler, M. L., Burguera, B. G., Pantalone, K. M., & Rotroff, D. M. (2026) · Obesity · doi:10.1002/oby.70163
Tirzepatide and semaglutide: different twins?
Cesaro, A., Acerbo, V., & Calabrò, P. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag028
Eisa, N., & Barood, O. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.003 · Cited by 2
How to reduce side effects of GLP-1 based obesity medications
Alhazmi, A., & le Roux, C. W. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.02.001
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Adeoye, O. O., Gesink, D., Dzyubak, O., Ferguson, S. E., & Kim, S. R. (2026) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2026.102058 · Cited by 1
Obesity, metabolic health status, and adverse outcomes in men and women
Ananda, R. A., Solomon, B. D., Nicholls, S. J., & Ray, K. K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101556 · Cited by 2
Tabor, H., Ediripolage, F., Akram, N., Afzal, I., & Radha, S. S. (2026) · Cureus · doi:10.7759/cureus.105269 · Cited by 1
Singh, S., Kumar, R., Maharshi, V., Sinha, N., & Payra, S. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_357_2025
Can weight-loss pills replace injectables? What the science says
Lenharo, M. (2026) · Nature · doi:10.1038/d41586-026-00856-7
Martino, J. A., Oles, A. R., Rogalski, B. L., Eichinger, J. K., & Friedman, R. J. (2026) · Shoulder & Elbow · doi:10.1177/17585732261434004
Incretin polyagonists as an alternative to bariatric surgery to manage obesity
Manoj, R. J., Fernandez, C. J., Nair, S., & Pappachan, J. M. (2026) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v17.i1.118132
Marassi, M., Pollis, R. M., & Fadini, G. P. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104714
Targeting the gut microbiota as a treatment for obesity and cancer cachexia
Giannakogeorgou, A., van den Ende, T., Verhaar, B. J. H., de Clercq, N. C., van Laarhoven, H. W. M., & Nieuwdorp, M. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2650180
Prise en charge du surpoids et de l’obésité en préopératoire
Pardo, E. (2026) · Le Praticien en Anesthésie Réanimation · doi:10.1016/j.pratan.2026.02.007
On the potential of group-specific component (GC) inhibition for treating metabolic disease
Gill, R. D., & Kuo, T. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.195
Rajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Park, D. J., Kim, Y., Jeon, D., Park, Y. H., Seo, K. W., & Kim, K. H. (2026) · Kosin Medical Journal · doi:10.7180/kmj.26.154
Thirugnanam, A. M., Chandrakanth, & Pruthvi (2026) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2026.03.011
Baumal, C. R., Choi, S. H., Balonov, K., & Diana, V. (2026) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20260310-01 · Cited by 1
Jain, R. (2026) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_94_25
Rahimpour, A., Stuart, I. G., Hyde, J., Roberts-Moore, K., Price, K. R., Keefer, J., Persily, A., Bown, P., & Barry, R. G. (2026) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000007620
Shen, P., Peng, M., Kim, S. J., Joung, K.-I., & Kim, K. J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344289 · Cited by 2
Obesity Management in End-Stage Kidney Disease: Pathways to Improve Kidney Transplant Access
Budhiraja, P., & Orandi, B. J. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.11.019 · Cited by 1
Sillassen, C. D. B., Faltermeier, P., Bjerg, J. L., Andersen, R. K., Petersen, J. J., Andersen, P. B., Kamp, C. B., Karlsson, F., Grand, J., Domínguez, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04824-w · Cited by 3
Alzaki, A. A., Alqahtani, M., Aman, E., Asiri, G. M., Jibril, M. H. A., Desoky, R. M., Alqahtani, S. A., Suhaqi, L., Alkhalid, S. A., Alshareef, D. Y., et al. (2026) · Cureus · doi:10.7759/cureus.106038 · Cited by 3
A Content Analysis of Web Pages on “Weight-Loss Injections”
Asuman, O. K. U. R. (2026) · Cerasus journal of medicine. · doi:10.70058/cjm.1852434
Tirzepatide during Ramadan in people with obesity without diabetes: A critical knowledge gap
Monjur, M. R. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70545
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., Cobellis, L., Cobellis, F., & Pilone, V. (2026) · Nutrients · doi:10.3390/nu18071092
Tirzepatide in Egypt: A New Era in Type 2 Diabetes and Obesity Management
Ghazi, H. A. (2026) · doi:10.5005/jodec-11035-0006 · Cited by 1
Papadakis, Z. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.03.103 · Cited by 1
Miedviedieva, K., Regoli, T., Marchisotta, S., Sessa, L., Blasco, M., Leanza, S., Ciuoli, C., Cantore, A., Ricci, C., & Cantara, S. (2026) · Genes · doi:10.3390/genes17040405
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
Agrawal, P. K., Samajdar, S. S., Garg, R., Gupta, G., Gautam, A., Husain, N., Mukherjee, S., & Panda, S. K. (2026) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_373_25
Afanaseva, A. N., Saparova, V. B., Ermolaeva, D. О., Makarenko, I. E., & Васильевич, Д. Р. (2026) · Drug development & registration · doi:10.33380/2305-2066-2026-15-2-2145
Targeting Multiple Gut‐Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy
Miras, A. D., & Hussain, M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70141 · Cited by 1
Jarso, G., Mahendru, S., Dutta, A., Sharma, R., Megerso, A., & Mithal, A. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_1085_25
How Somatic Mutations cause Aging without Causing AgingPreprint
Wolf, A. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6431458
Omeh, Z., Khan, T., Uthman, O., & Barber, T. M. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2656247
Mifsud, F. (2023) · theses.fr (ABES) · doi:10.70675/5545c0dfz1da3z4654z857fz6194d42cd43d
Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
姚, 张. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641386
Larusdottir, A. E., Teitsdottir, U. D., Tragante, V., Pálsson, F., Kristinsdottir, A. M., Eldjárn, G. H., Stefánsdóttir, L., Oddsson, Á., Aegisdottir, H. M., Styrkársdóttir, U., et al. (2026) · Nature Communications · doi:10.21203/rs.3.rs-9238373/v1
The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
Jafari, S. M. S., Caro, G., Lipner, S. R., & Iorizzo, M. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01021-6 · Cited by 4
Khan, S., Khan, S. S., Mouazen, S. M., Ramadan, Z. M., Khan, S. S., Aldawood, Y. O., & Neto, M. G. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08588-3
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Daily Predictors of Resistance Training Behavior Among Glucagon-Like Peptide 1 Users
Kompf, J. M., & Rhodes, R. E. (2026) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000347
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Hunter, T. M., Leith, A., Harrison, L., Gerber, C., Raikar, S. K., Ashok, G., & Artime, E. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03580-w
Olagunju, A. S., Babalola, A. D., Najophe, S. E., Farodoye, O. M., Otenaike, T. A., Godswill, U.-A. S., & Teibo, J. O. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01764-9 · Cited by 1
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · medRxiv · doi:10.64898/2026.04.11.26350687
The role and mechanism of UPRmt in adipocytes
Liu, H.-N., Chen, J., Qiu, D.-Q., Jiang, M., Chen, H.-Q., Li, L., & Chen, S.-Q. (2026) · Adipocyte · doi:10.1080/21623945.2026.2651605
The evolving landscape of metabolic surgery: An evidence-based review
Dholakia, V., Das, S., & Nundy, S. (2026) · Journal of Minimal Access Surgery · doi:10.4103/jmas.jmas_551_25
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Zarówna, K., Pura, W., Mazur, J., Marciniak, J., Kosowski, M., Matecka, D., Śliwiński, W., & Chołuj, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4791
Zhou, Q., & Shen, Y. (2026) · Clinical Proteomics · doi:10.1186/s12014-026-09583-7
Adamidis, N., Adamidi, S., GEORGAKOPOULOU, V. E., & Adamidis, S. (2026) · Cureus · doi:10.7759/cureus.107073
GLP-1-Rezeptoragonisten bei Übergewicht
Weiler, S., & Egermann, U. (2026) · pharma-kritik · doi:10.37667/pk.2026.1450
Мамедов, М. Н., Друк, И. В., & Akhundova, H. R. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6812
Nephroprotektion – Diabetes und Adipositas
Boger, L. (2026) · Nephrologie aktuell · doi:10.1055/a-2748-5160
Alawadi, F., Abdelgadir, E., Hassoun, A. A. K., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Alkaabi, J., Bashier, A. M., Bayado, F., Belaila, B. A. B., et al. (2026) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v32i1.21067
International consensus on adolescent metabolic health: prevention of obesity and type 2 diabetes
Shaltout, I., Schwarz, P. E. H., Meligi, A. A. H. E., Sherif, I. E., Hammad, H., Abdelghaffar, S., Hegazy, M., Nasr, G. M., Habeeb, H., Barakat, E., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02142-y · Cited by 2
Increased Levothyroxine Requirement After Tirzepatide Initiation
Koç, D., & Keskinler, M. V. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.04.007 · Cited by 1
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
Xie, J., Huang, J., Wu, Q., Deng, K., Yang, S., Yang, S., Wu, S., Yang, X., Huang, W., Yanrong, D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70794
Acucella, G. A., & Caponio, D. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70225 · Cited by 1
Abegaz, T. M., Frietze, G. A., Bhagavathula, A. S., & Ali, A. A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103060
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Lin, C., Chen, W., Liu, S. X., Cao, B., Ge, Y., Li, Y., Liu, Y., Guo, T., Xu, J., & Wang, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-115236
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
Awadalla, L., Iskander, S., Chu, C., & Tadrous, M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0248 · Cited by 1
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.